title: A TGF betaRII frameshift-mutation-derived CTL epitope recognised by HLA-A2-restricted CD8+ T cells.
abstract: Microsatellite instability (MSI) is recognised as genome-wide alterations in repetitive DNA sequences caused by defects in the DNA mismatch repair machinery. Such mutation patterns have been found in almost all analysed malignancies from patients with hereditary non-polyposis colorectal cancer, and in approximately 15% of sporadic colorectal cancers. In cancers with the MSI phenotype, microsatellite-like sequences in coding regions of various cancer-related genes, including transforming growth factor beta receptor type II (TGF betaRII), are targets for mutations. The TGF betaRII gene harbours a 10-bp polyadenine tract, and mutations within this region are found in 90% of colorectal cancers with MSI. The frameshift mutations result in new amino acid sequences in the C-terminal part of the proteins, prematurely terminating where a novel stop codon appears. In this study we have defined new cytotoxic T lymphocyte (CTL) epitope (RLSSCVPVA), carrying a good HLA-A*0201 binding motif, and resulting from the most common frameshift mutation in TGF betaRII. A CTL line and several CTL clones were generated from an HLA-A2+ normal donor by repeated stimulation of T cells with dendritic cells pulsed with the peptide. One of the CTL clones was able to kill an HLA-A2+ colon cancer cell line harbouring mutant TGF betaRII. This epitope may be a valuable component in cancer vaccines directed at MSI-positive carcinomas.
authors.affiliation: Department of Immunology, The Norwegian Radium Hospital, University of Oslo, Montebello. ingvil.saterdal@labmed.uio.no
authors.forename: I
authors.initials: I
authors.lastname: Saeterdal
authors.forename: M K
authors.initials: MK
authors.lastname: Gjertsen
authors.forename: P
authors.initials: P
authors.lastname: Straten
authors.forename: J A
authors.initials: JA
authors.lastname: Eriksen
authors.forename: G
authors.initials: G
authors.lastname: Gaudernack
mesh_terms: D000595:Amino Acid Sequence; D000951:Antigens, Neoplasm / Q000627:therapeutic use; D001483:Base Sequence; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D019496:Cancer Vaccines / Q000627:therapeutic use; D002460:Cell Line; D002470:Cell Survival; D002857:Chromium / Q000378:metabolism; D003713:Dendritic Cells / Q000276:immunology; D018984:Epitopes, T-Lymphocyte / Q000276:immunology*; D005434:Flow Cytometry; D016368:Frameshift Mutation; D015789:HLA-A2 Antigen / Q000276:immunology*; D006801:Humans; D008969:Molecular Sequence Data; D010455:Peptides / Q000378:metabolism; D016133:Polymerase Chain Reaction; D017346:Protein Serine-Threonine Kinases; D000077294:Receptor, Transforming Growth Factor-beta Type II; D011948:Receptors, Antigen, T-Cell / Q000032:analysis; D018125:Receptors, Transforming Growth Factor beta / Q000235:genetics*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D016212:Transforming Growth Factor beta / Q000235:genetics
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D018984:Epitopes, T-Lymphocyte; D015789:HLA-A2 Antigen; D010455:Peptides; D011948:Receptors, Antigen, T-Cell; D018125:Receptors, Transforming Growth Factor beta; D016212:Transforming Growth Factor beta; D002857:Chromium; D017346:Protein Serine-Threonine Kinases; D000077294:Receptor, Transforming Growth Factor-beta Type II